Loading
A phase 1/2 trial of HMBD-001, Docetaxel, Cetuximab in non-small-cell lung cancer, run by Hummingbird Bioscience, now recruiting.
A Phase Ib/II Study of an Anti-HER3 Antibody, HMBD-001, With Cetuximab +/- Docetaxel in Advanced Squamous Cell Cancers is a phase 1/2 interventional study registered as NCT05910827 by Hummingbird Bioscience, with 398 participants planned, started 2024-02-05 and due to reach its primary completion in 2027-12-01. Interventions recorded: HMBD-001, Docetaxel, Cetuximab. Conditions listed: Advanced or Metastatic Squamous Non-Small Cell Lung Cancer, Advanced Head and Neck Squamous Cell Carcinoma, Advanced Esophageal Squamous Cell Carcinoma, Cervical Squamous Cell Carcinoma. No results are recorded here; the registry entry is the source.
The full inclusion and exclusion criteria are on the registry record. Read 2026-10-07. Recruiting overall does not mean a particular site is open; ask the study team.
ClinicalTrials.gov data courtesy of the US National Library of Medicine.
Shares Cetuximab, Monoclonal antibodies, Head and neck squamous cell carcinoma.
Shares Cetuximab, Docetaxel, Head and neck squamous cell carcinoma, Non-small-cell lung cancer.
Shares Docetaxel, Cytotoxic chemotherapy, Non-small-cell lung cancer.
Shares Cetuximab, Monoclonal antibodies, Head and neck squamous cell carcinoma.
Shares Cutaneous squamous cell carcinoma, Head and neck squamous cell carcinoma, Non-small-cell lung cancer.
Shares Docetaxel, Monoclonal antibodies, Cytotoxic chemotherapy, Non-small-cell lung cancer.
Shares Cutaneous squamous cell carcinoma, Head and neck squamous cell carcinoma, Non-small-cell lung cancer.
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/